Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage For the treatment of severe psoriasis in adults.
Marketing Status approved
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 17337-0003; 59981-011; 0093-1136; 0115-1752; 42291-087; 62147-0145; 0115-1751; 42794-081; 0378-7020; 71214-0698; 42291-088; 58159-058; 71052-692; 0115-1753; 17337-0004; 71214-0667; 0115-1750; 71214-0668; 71214-0669; 42291-086; 42794-080; 0093-1135; 0093-1138; 62147-0146; 76055-0001; 42794-083; 0378-7023
UNII LCH760E9T7
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disease progression08.01.03.0380.001250%
Drug intolerance08.06.01.013---
Occult blood13.05.02.003---
Hyperlipidaemia14.08.03.001--
Urine analysis abnormal13.13.02.008---
Renal impairment20.01.03.0100.003124%-
Skin haemorrhage23.06.07.001; 24.07.01.1030.001250%-
Ulcerative keratitis06.04.02.004; 10.02.01.021--
Cytopenia01.03.03.012---
Treatment failure08.06.01.0170.003374%-
Skin mass23.07.04.014---
Anorectal discomfort07.03.03.003---
Fasting26.01.02.001---
Drug-induced liver injury09.01.07.023; 12.03.01.0440.001875%-
Candida infection11.03.03.021--
Excessive cerumen production04.01.01.004---
Liver function test increased13.03.04.031---
Malignant melanoma in situ16.03.01.004; 23.08.01.0040.001250%-
Diabetic foot05.07.06.001; 14.07.06.001; 17.09.04.006; 23.07.03.008; 24.04.03.015---
Skin plaque23.03.03.044---
Toxic goitre05.02.02.006; 14.11.01.0460.001250%-
Burning feet syndrome15.03.04.019; 17.02.06.038; 23.06.05.010---
Cutaneous T-cell lymphoma01.11.03.002; 16.17.03.002; 23.07.04.0290.001875%-
Differentiation syndrome08.01.07.016; 12.03.01.063; 16.32.03.037; 22.02.01.0360.003124%-
Diffuse idiopathic skeletal hyperostosis15.01.09.0060.001250%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.001875%-
Idiopathic intracranial hypertension17.07.02.0110.001250%-
Immune thrombocytopenia01.08.01.013; 10.02.01.0830.001250%-
Therapeutic product effect decreased08.06.01.050---
Therapeutic product effect incomplete08.06.01.0520.003124%-
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene